The second cIMPACT-NOW (the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy-Not Official WHO) update from 2018 opened for refraining from direct 1p/19q testing in IDH-mutant DLGGs with unambiguous astrocytic phenotype, given strong p53 immunopositivity and/or definite loss of nuclear expression of ATRX (alpha-thalassemia/mental retardation, X-linked).20 Since the CRF solely contained questions regarding mutational status of IDH and 1p/19q, data on assessments of ATRX and TP53 were not available. The gene discussed is ATRX; the disease is central nervous system neoplasm.